Comparative effects of cyproterone acetate or a long-acting LHRH agonist in polycystic ovarian disease.
A randomized cross-over study was done to compare the therapeutic efficacy of cyproterone acetate (CPA, 50 mg/day orally) and a depot preparation of the LHRH superagonist (D-Trp6 LHRH 3 mg i.m. once a month) in 10 patients with polycystic ovarian disease (PCO). The two treatment periods were separated by 6 months. Both treatments resulted in marked clinical improvement. In response to CPA treatment, basal plasma gonadotropin, estradiol, estrone, testosterone and androstenedione levels significantly decreased. In response to D-Trp6 LHRH, both basal and stimulated gonadotropin levels were completely suppressed after 3 weeks of treatment. After initial elevation on day 2, plasma ovarian steroid levels fell into the castrate range, without any change in dehydroepiandrosterone sulfate levels. Urinary 3 alpha-androstanediol excretion decreased significantly. In patients with PCO, LHRH-A induced more complete gonadotropin inhibition than did CPA. However, following cessation of either therapy, the disease rapidly recurred.
Schaison
G
G
Service d'Endocrinologie et des Maladies de la Reproduction, Hôpital de Bicêtre, France.
Couzinet
B
B
D000328:Adult; D000728:Androgens / Q000097:blood; D002986:Clinical Trials as Topic; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D003692:Delayed-Action Preparations; D004958:Estradiol / Q000097:blood; D004970:Estrone / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism; D008186:Luteolytic Agents / Q000627:therapeutic use; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D011897:Random Allocation; D017329:Triptorelin Pamoate
D000728:Androgens; D003692:Delayed-Action Preparations; D008186:Luteolytic Agents; D017329:Triptorelin Pamoate; D004970:Estrone; D007987:Gonadotropin-Releasing Hormone; D017373:Cyproterone Acetate; D004958:Estradiol; D007986:Luteinizing Hormone; D003534:Cyproterone